Scabies in the developing world-its prevalence, complications, and management

Clinical Microbiology and Infection

Volumn 18, Issue 4, 2012, Pages 313-323

  Hay, R J ^a   Steer, A C ^b   Engelman, D ^b   Walton, S ^c  

^a International Foundation for Dermatology   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

Developing countries; Glomerulonephritis; Neglected tropical diseases; Rheumatic fever; Scabies

Indexed keywords

BENZYL BENZOATE; CROTAMITON; EUGENOL; IVERMECTIN; LINDANE; MALATHION; MOXIDECTIN; PERMETHRIN; SULFUR; TEA TREE OIL;

ACUTE GLOMERULONEPHRITIS; APLASTIC ANEMIA; APPLICATION SITE BURNING; CLINICAL FEATURE; CONVULSION; DEVELOPING COUNTRY; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG EFFICACY; GROUP A STREPTOCOCCAL INFECTION; HEMATURIA; HUMAN; INFESTATION; KIDNEY INJURY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PYODERMA; REVIEW; SARCOPTES SCABIEI; SCABIES; SEPTICEMIA; SKIN IRRITATION; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE; TH17 CELL; UNSPECIFIED SIDE EFFECT;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS SP. 'GROUP A';

EID: 84858627615     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03798.x     Document Type: Review

References (111)

1. Andrews RM, McCarthy J, Carapetis JR, Currie BJ. Skin disorders, including pyoderma, scabies, and tinea infections. Ped Clin North Am 2009; 56: 1421-1440.
2. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis 2004; 4: 240-245.
3. Chosidow O. Clinical practices. Scabies. N Engl J Med 2006; 20: 354-356.
4. World Health Organization. Epidemiology and management of common skin diseases in children in developing countries. Geneva: WHO, 2005.
5. Nair BK, Joseph A, Kandamuthan M. Epidemic scabies. Indian J Med Res 1977; 65: 513-518.
6. Carapetis JR, Connors C, Yarmirr D, Krause V, Currie BJ. Success of a scabies control program in an Australian aboriginal community. Pediatr Infect Dis J 1997; 16: 494-499.
7. Currie BJ, Connors CM, Krause VL. Scabies programs in aboriginal communities. Med J Aust 1994; 161: 636-637.
8. World Health Organization. The current evidence for the burden of group A streptococcal diseases. 2005. Geneva: WHO, 2005.
9. Steer AC, Jenney AW, Kado J et al. High burden of impetigo and scabies in a tropical country. PLoS Negl Trop Dis 2009; 3: e467.
10. Andrews JR. Scabies in New Zealand. Int J Dermatol 1979; 18: 545-552.
11. Savin JA. Scabies in Edinburgh from 1815 to 2000. J R Soc Med 2005; 98: 124-129.
12. Christophersen J. The epidemiology of scabies in Denmark, 1900 to 1975. Arch Dermatol 1978; 114: 747-750.
13. Burkhart CG, Burkhart CN, Burkhart KM. An epidemiologic and therapeutic reassessment of scabies. Cutis 2000; 65: 233-240.
14. Mimouni D, Gdalevich M, Mimouni FB, Haviv J, Ashkenazi I. The epidemiologic trends of scabies among Israeli soldiers: a 28-year follow-up. Int J Dermatol 1998; 37: 586-587.
15. McCarthy JS, Kemp DJ, Walton SF, Currie BJ. Scabies: more than just an irritation. Postgrad Med J 2004; 80: 382-387.
16. dos Santos MM, Amaral S, Harmen SP et al. The prevalence of common skin infections in four districts in Timor-Leste: a cross sectional survey. BMC Infect Dis 2010; 10: 61-66.
17. Burkhart CG. Scabies: an epidemiologic reassessment. Ann Intern Med 1983; 98: 498-503.
18. Landwehr D, Keita SM, Ponnighaus JM, Tounkara C. Epidemiologic aspects of scabies in Mali, Malawi, and Cambodia. Int J Dermatol 1998; 37: 588-590.
19. Gulati PV, Singh KP, Braganza C. Role of sociocultural and environmental factors in the cause of scabies. Int J Dermatol 1977; 16: 281-283.
20. Heukelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbidity of scabies and pediculosis capitis in resource-poor communities in Brazil. Br J Dermatol 2005; 153: 150-156.
21. Terry BC, Kanjah F, Sahr F et al. Sarcoptes scabiei infestation among children in a displacement camp in Sierra Leone. Public Health 2001; 115: 208-211.
22. Muhammad Zayyid M, Saidatul Saadah R, Adil AR, Rohela M, Jamaiah I. Prevalence of scabies and head lice among children in a welfare home in Pulau Pinang, Malaysia. Trop Biomed 2010; 27: 442-446.
23. Pruksachatkunakorn C, Wongthanee A, Kasiwat V. Scabies in Thai orphanages. Pediatr Int 2003; 45: 724-727.
24. Figueroa JI, Fuller LC, Abraha A, Hay RJ. Skin disease in southwestern Ethiopia: rationale for a community approach. Int J Dermatol 1998; 37: 752-758.
25. Luby SP, Agboatwalla M, Feikin DR et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 2005; 366: 185-187.
26. Walton SF, Currie BJ. Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev 2007; 20: 268-279.
27. Mimouni D, Ankol OE, Davidovitch N et al. Seasonality trends of scabies in a young adult population: a 20-year follow-up. Br J Dermatol 2003; 149: 157-159.
28. Sokolova TV, Radchenko MI, Lange AB. The seasonality of scabies morbidity and the fertility of the itch mite Sarcoptes scabiei de Geer as an index of the activity of a population of the causative agent. Vestn Dermatol Venerol 1989; 11: 12-15.
29. Hengge UR, Currie BJ, Jager G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis 2006; 6: 769-779.
30. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect 2005; 50: 375-381.
31. Gogna NK, Lee KC, Howe DW. Norwegian scabies in Australian Aborigines. Med J Aust 1985; 21: 142-144.
32. Mellanby K. The development of symptoms, parasitic infection and immunity in human scabies. Parasitology 1944; 35: 197-206.
33. Currie BJ, Maguire GP, Wood YK. Ivermectin and crusted (Norwegian) scabies. Med J Aust 1995; 163: 559-560.
34. Walton SF, Choy JL, Bonson A et al. Genetically distinct dog-derived and human-derived Sarcoptes scabiei in scabies-endemic communities in northern Australia. Am J Trop Med Hyg 1999; 61: 542-547.
35. Walton SF, Dougall A, Pizzutto S et al. Genetic epidemiology of Sarcoptes scabiei (Acari: Sarcoptidae) in northern Australia. Int J Parasitol 2004; 34: 839-849.
36. Mellanby K. The transmission of scabies. BMJ 1941; 2: 405-406.
37. Johnson CG, Mellanby K. The parasitology of human scabies. Parasitology 1942; 34: 285-290.
38. Elgart M, Scabies L. Dermatol Clinics 1990; 8: 253-263.
39. Arlian LG, Runyan RA, Achar S, Estes SA. Survival and infestivity of Sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol 1984; 11: 210-215.
40. Arlian LG, Runyan RA, Estes SA. Cross infestivity of Sarcoptes scabiei. J Am Acad Dermatol 1984; 10: 979-986.
41. Fischer K, Holt DC, Harumal P et al. Generation and characterisation of cDNA clones from Sarcoptes scabiei var. hominis for an expressed sequence tag library: identification of homologues of house dust mite allergens. Am J Trop Med Hyg 1984; 2003; 68: 61-64.
42. Walton SF. The immunology of susceptibility and resistance to scabies. Parasite Immunol 2010; 32: 532-540.
43. Walton SF, Beroukas D, Roberts-Thomson P, Currie BJ. New insights into disease pathogenesis in crusted (Norwegian) scabies: the skin immune response in crusted scabies. Br J Dermatol 2008; 158: 1247-1255.
44. Walton SF, Pizzutto S, Slender A et al. Increased allergic immune response to Sarcoptes scabiei antigens in crusted versus ordinary scabies. Clin Vaccine Immunol 2010; 17: 1428-1438.
45. Jayaraj R, Hales B, Viberg L et al. A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabiei. Diagn Microbiol Infect Dis 2011; 71: 403-407.
46. Morgan MS, Arlian LG. Response of human skin equivalents to Sarcoptes scabiei. J Med Entomol 2011; 47: 877-883.
47. Elder BL, Arlian LG, Morgan MS. Sarcoptes scabiei (Acari: Sarcoptidae) mite extract modulates expression of cytokines and adhesion molecules by human dermal microvascular endothelial cells. J Med Entomol 2006; 43: 910-915.
48. Elder BL, Arlian LG, Morgan MS. Modulation of human dermal microvascular endothelial cells by Sarcoptes scabiei in combination with proinflammatory cytokines, histamine, and lipid-derived biologic mediators. Cytokine 2009; 47: 103-111.
49. Mullins JS, Arlian LG, Morgan MS. Extracts of Sarcoptes scabiei De Geer downmodulate secretion of IL-8 by skin keratinocytes and fibroblasts and of GM-CSF by fibroblasts in the presence of proinflammatory cytokines. J Med Entomol 2009; 46: 845-851.
50. Wikel SK. Acquired resistance to ticks: expression of resistance by C4-deficient guinea pigs. Am J Trop Med Hyg 1979; 28: 586-590.
51. Zipfel PF, Wurzner R, Skerka C. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol Immunol 2007; 44: 3850-3857.
52. Mika A, Goh P, Holt DC, Kemp DJ, Fischer K. Scabies mite peritrophins are potential targets of human host innate immunity. PLoS Negl Trop Dis 2011; 5: e1331.
53. Holt DC, Fischer K, Allen GE et al. Mechanisms for a novel immune evasion strategy in the scabies mite Sarcoptes scabiei: a multigene family of inactivated serine proteases. J Invest Dermatol 2003; 121: 1419-1424.
54. Bergstrom FC, Reynolds S, Johnstone M et al. Scabies mite inactivated serine protease paralogs inhibit the human complement system. J Immunol 2009; 182: 7809-7817.
55. Milner JD, Brenchley JM, Laurence A et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452: 773-776.
56. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128: 1064-1067.
57. Beckham SA, Boyd SE, Reynolds C et al. Characterization of a serine protease homologous to house dust mite group 3 allergens from the scabies mite Sarcoptes scabiei. J Biol Chem 2009; 284: 34413-34422.
58. Reid HF, Birju B, Holder Y, Hospedales J, Poon-King T. Epidemic scabies in four Caribbean islands, 1981-1988. Trans R Soc Trop Med Hyg 1990; 84: 298-300.
59. Currie BJ, Carapetis JR. Skin infections and infestations in Aboriginal communities in northern Australia. Aust J Dermatol 2001; 41: 139-143.
60. Mahé A, Prual A, Konaté M, Bobin P. Skin diseases of children in Mali: a public health problem. Trans R Soc Trop Med Hyg 1995; 89: 467-470.
61. Terry BC, Kanjah F, Sahr F et al. Sarcoptes scabiei infestation among children in a displacement camp in Sierra Leone. Public Health 2001; 11: 208-211.
62. Murdoch M, Hay RJ, Mackenzie CD et al. A new clinical classification for the skin lesions of onchocerciasis. Br J Dermatol 1993; 129: 260-269.
63. Prins C, Stucki L, French L et al. Dermoscopy for the in vivo detection of Sarcoptes scabiei. Dermatology 2004; 208: 241-243.
64. Bezold G, Lange M, Schiener R et al. Hidden scabies: diagnosis by polymerase chain reaction. Br J Dermatol 2001; 144: 614-618.
65. Mahe A, Faye O, N'Diaye HT et al. Definition of an algorithm for the management of common skin diseases at primary health care level in sub-Saharan Africa. Trans R Soc Trop Med Hyg 2005; 99: 39-47.
66. Steer AC, Tikoduadua LV, Manalac M et al. Validation of an integrated management of childhood illness algorithm for managing common skin conditions in Fiji. Bull WHO 2009; 87: 173-179.
67. Hay RJ, Mahé A, Estrada R et al. Skin disease. In: Jamison DT, Breman JG, Measham AR et al., eds. Disease control priorities in developing countries. New York: World Bank and Oxford Universiity Press Publications, 2006; 707-722.
68. Streeton L, Hanna JN, Messer RD. An epidemic of acute post-streptococcal glomerulonephritis among Aboriginal children. J Paediatr Child Health 2008; 31: 245-248.
69. Bessen DE, Carapetis JR, Beall B et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 2000; 182: 1109-1116.
70. White AV, Hoy WE, McCredie DA. Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life. Med J Aust 2001; 174: 492-496.
71. Lawrence G, Leafasia J, Sheridan J et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull WHO 2005; 83: 34-42.
72. Mulholland EK, Ogunlesi OO, Adegbola RA et al. Etiology of serious infections in young Gambian infants. Pediatr Infect Dis J 2015; 18: S35-S41.
73. Hay RJ, Estrada Castenon R, Alarcon H et al. Wastage of family income on skin disease-a study of skin infection in Guerrero, Mexico. BMJ 1994; 309: 848-849.
74. Wooltorton E. Concerns over lindane treatment for scabies and lice. CMAJ 2003; 27: 168.
75. Elgart ML. A risk-benefit assessment of agents used in the treatment of scabies. Drug Saf 1996; 14: 386-393.
76. Chosidow O. Scabies and pediculosis. Lancet 2000; 355: 819-826.
77. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007; CD000320
78. Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg 2000; 94: 92-96.
79. Walton SF, McKinnon M, Pizzutto S et al. Acaricidal activity of Melaleuca alternifolia (tea tree) oil: in vitro sensitivity of Sarcoptes scabiei var. hominis to terpinen-4-ol. Arch Dermatol 2004; 140: 563-566.
80. Pasay C, Mounsey K, Stevenson G et al. Acaricidal activity of eugenol based compounds against scabies mites. PLoS One 2010; 5: e12079.
81. Oladimeji FA, Orafidiya OO, Ogunniyi TA, Adewunmi TA. Pediculocidal and scabicidal properties of Lippia multiflora essential oil. J Ethnopharmacol 2000; 72: 305-311.
82. Scott G. United Kingdom national guideline on the management of scabies infestation. British Association of Sexual Health and HIV, 2007. Available at: (last accessed on 3 November 2011).
83. Usha V, Nair TVG. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236-240.
84. Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health 2002; 38: 401-404.
85. Sule HM, Thacher TD. Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients. Am J Trop Med Hyg 2007; 76: 392-395.
86. Glaziou P, Cartel JL, Alzieu P et al. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol Res 1993; 44: 331-332.
87. Nnoruka EN. Successful treatment of scabies with oral ivermectin in Nigeria. Trop Doct 2001; 31: 15-18.
88. Ly F, Caumes E, Ndaw CAT, Ndiayed B, Mahé A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull WHO 2009; 87: 424-430.
89. Steer AC, Kearns T, Andrews RM, McCarthy JS, Carapetis JR, Currie BJ. Ivermectin worthy of further investigation. Bull WHO 2009; 87: A; author reply B.
90. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis 2004; 39: e8-e12.
91. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010; 362: 717-725.
92. Arlian LG, Estes SA, Vyszenski-Moher DL. Prevalence of Sarcoptes scabiei in the homes and nursing homes of scabietic patients. J Am Acad Dermatol 1988; 19: 806-811.
93. Wolf R, Davidovici B. Treatment of scabies and pediculosis: facts and controversies. Clin Dermatol 2010; 28: 511-518.
94. Currie BJ, Carapetis JR. Skin infections and infestations in Aboriginal communities in northern Australia. Aust J Dermatol 2000; 41: 139-143.
95. Kanaaneh HA, Rabi SA, Badarneh SM. The eradication of a large scabies outbreak using community-wide health education. Am J Public Health 1976; 66: 564-567.
96. Wong LC, Amega B, Connors C et al. Outcome of an interventional program for scabies in an indigenous community. Med J Aust 2001; 175: 367-370.
97. Taplin D, Porcelain SL, Meinking TL et al. Community control of scabies: a model based on use of permethrin cream. Lancet 1991; 337: 1016-1018.
98. Andrews RM, Kearns T, Connors C et al. A regional initiative to reduce skin infections amongst aboriginal children living in remote communities of the Northern Territory, Australia. PLoS Negl Trop Dis 2009; 3: e554.
99. Bockarie MJ, Alexander ND, Kazura JW et al. Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Trop 2000; 25: 75-77.
100. Wong LC, Amega B, Barker R et al. Factors supporting sustainability of a community-based scabies control program. Aust J Dermatol 2002; 43: 274-277.
101. La Vincente S, Kearns T, Connors C et al. Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis 2009; 3: e444.
102. Ciftci IH, Karaca S, Dogru O et al. Prevalence of pediculosis and scabies in preschool nursery children of Afyon, Turkey. Korean J Parasitol 2006; 44: 95-98.
103. Ogunbiyi AO, Owoaje E, Ndahi A. Prevalence of skin disorders in school children in Ibadan, Nigeria. Pediatr Dermatol 2005; 22: 6-10.
104. Walker SL, Shah M, Hubbard VG et al. Skin disease is common in rural Nepal: results of a point prevalence study. Br J Dermatol 2008; 158: 334-338.
105. Yap FB-B, Elena E, Pabalan M. Prevalence of scabies and head lice among students of secondary boarding schools in Kuching, Sarawak, Malaysia. Pediatr Infect Dis J 2010; 29: 682-683.
106. Feldmeier H, Jackson A, Ariza L et al. The epidemiology of scabies in an impoverished community in rural Brazil: presence and severity of disease are associated with poor living conditions and illiteracy. J Am Acad Dermatol 2009; 60: 436-443.
107. Pasay C, Walton S, Fischer K et al PCR-based assay to survey for knockdown resistance to pyrethroid acaricides in human scabies mites (Sarcoptes scabiei var. hominis). Am J Trop Med Hyg 2006; 74: 649-657.
108. Nolan K, Kamrath J, Levitt J et al. Lindane toxicity: a comprehensive review of the medical literature. Pediatr Dermatol 2011; 13: 246-250.
109. Boix V, Sanchez-Paya J, Portilla J et al. Nosocomial outbreak of scabies clinically resistant to lindane. Infect Control Hosp Epidemiol 1997; 18: 677-678.
110. Heukelbach J, Winter B, Wilcke T et al. Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull WHO 2004; 82: 563-571.
111. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997; 349: 1144-1145.